Vivos Inc (RDGL)

[bdvest]

Agree no more! A biopharma company even just in the stage of preclinical or early stage of clinical trials, no mention whether the pipeline will succeed or not, it is worthy of more than 10 M to couple 100 M. Vivos already has animal effectiveness approved products device as isopet, the very resistant soft tissue sarcomas were well controlled and proved by three lucky dog patients, how come human verison, the radiogel can not prevail? not mentioning so many types of solid cancers, such as breast cancer, prostate cancer, brain cancers and so on.
RDGL is very undervalued now, smart money is coming in especially from other countries, we will see!